StemCell Therapy

Tumor necrosis factor inhibitors (TNFis) have comparable effectiveness to non-TNFis in the treatment of rheumatoid arthritis (RA), according to study data published in Annals of the Rheumatic Diseases.

Investigators extracted data from the Consortium of Rheumatology Researchers of North America RA Registry, a large healthcare database of patients with RA in the United States. Adult patients with clinician-diagnosed RA and a Clinical Disease Activity Index (CDAI) >2.8 were eligible for inclusion in the study. Patients who were initiated with a first-line TNFi or non-TNFi between 2001 and 2018 were enrolled. Patients with prior exposure to a biologic or targeted synthetic DMARD were excluded from the study. Baseline clinical and demographic characteristics were collected before treatment initiation. The primary outcome was change in CDAI at 1 year after initiation of TNFi or non-TNFi. Low disease activity was defined as CDAI 10; remission was defined as CDAI 2.8. Secondary end points included various patient-reported outcomes, such as quality of life, quality of sleep, fatigue, and morning stiffness. Groups were propensity score-matched at baseline. Random effect regression models were used to compare outcome measures between the TNFi and non-TNFi treatment groups.

The study cohort included 4816 individuals, among whom 4186 were with initiated a TNFi and 630 with a non-TNFi. The mean age of patients in the TNFi and non-TNFi groups were 56.912.7 years and 62.713.0 years, respectively. A majority of the TNFi and non-TNFi groups were women (76.5% and 79.8%, respectively).

Overall, both groups had significant improvements in RA symptoms and patient-reported quality of life. At 1 year, similar proportions of the TNFi and non-TNFi groups achieved low disease activity (39.9% and 41.6%, respectively; P =.87) and remission (17.6% vs 16.3%; P =.26). Both groups also had comparable improvements in mean changes in CDAI (P =.16), Health Assessment Questionnaire scores (P =.07), and patient-reported morning stiffness (P =.29) and fatigue (P =.42). After propensity matching, the TNFi vs non-TNFi groups had lower incidence of anemia (19.04 vs 24.01 cases per 100 person-years, respectively; P =.03). However, the 2 groups did not significantly differ on other outcomes.

Results indicated that both TNFi and non-TNFi treatment may be appropriate after the failure to respond to csDMARDs.

The findings of no significant differences in outcomes between first-line TNF and first-line non-TNF groups support RA guidelines which recommend [individualized] care based on clinical judgement and consideration of patient preferences, the investigators concluded.

Disclosures: This study was supported by Corrona, LLC, and the analysis was supported by Regeneron Pharmaceuticals, Inc, and Sanofi.

Pappas DA, St John G, Etzel CJ, et al. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study. Ann Rheum Dis. Published online July 21, 2020. doi:10.1136/annrheumdis-2020-217209

See original here:
TNF and Non-TNF Inhibitors Display Comparable Effectiveness for Rheumatoid Arthritis Treatment - Rheumatology Advisor

Arthritis and joint pain become very common as one age. From feeling the pain while sitting or standing to swellings in the joint, people are increasingly suffering from joint pain. Neck, back, knee, wrists pain have become overtly common during the lockdown because of long working hours. Sitting in one position for work for long hours is also a reason for people suffering from arthritis.

Arthritis isof two types. One is osteoarthritis that results from the breakdown of the cartilage and the other is rheumatoid arthritis which is caused by weak immunity. The reason behind all this is the lack of exercise and a bad lifestyle. Swami Ramdev, in a special show on India TV, shares effective yoga asanas and pranayamas that are effective in treating Arthritis and joint pain.

Swami Ramdev claims that sukshma vyayamas are very effective in keeping the joints flexible and protects the body from arthritis. He suggests doing yoga asanas like tadasanas, chakki asana, sthit konasana, makrasana, bhujangasana, markatasana, setubandh asana and uttanpadasana to treat neck, back and knee pain.

Swami Ramdev says that pranayamas maintain proper blood circulation in the body which helps keep our organs healthy. He suggests starting the day with surya namaskar and then perform pranayamas like kapalbhati, anulom vilom, and bhastrika for effective results. He says that one can do kapalbhati for half an hour to one hour. He also suggests increasing the number of pranayamas every week as your body gets used to it.

MoreBollywood storiesandpicture galleries

For all latestnewsandupdates,staytuned toourFacebookpage

Fight against Coronavirus: Full coverage

View original post here:
Treat Arthritis and Joint Pain with Swami Ramdev's effective yoga asanas - India TV News

It adds: "Controlling the rash or ulcers requires controlling the underlying inflammation."

According to the NHS, treatments can help reduce inflammation in the joints, relieve pain, prevent or slow down joint damage, reduce disability and enable you to be as active as possible.

"If you've been diagnosed with rheumatoid arthritis, you'll usually be offered a combination of DMARD tablets as part of your initial treatment," explains the health body.

These medicines ease the symptoms of the condition and slow down its progression.

It's also important to ensure your overall diet is still healthy and balanced.

"A Mediterranean-style diet, which is based on vegetables, fruits, legumes, nuts, beans, cereals, grains, fish and unsaturated fats such as olive oil, is recommended," says the NHS.

There's also some evidence to suggest that taking fish oil supplements may help reduce joint pain and stiffness caused by rheumatoid arthritis.

It is worth noting that some people with rheumatoid arthritis feel their symptoms get worse after they have eaten certain foods.

"If you think this may be the case for you, it may be useful to try avoiding problematic foods for a few weeks to see if your symptoms improve," advises the NHS.

Read the original:
Rheumatoid arthritis symptoms: The warning sign on your skin to watch out for - Express

Emphasising the point, a study published in the Oxford Journal of Rheumatology stated that 41 percent of those suffering from rheumatoid arthritis improved on a gluten-free diet conducted over a one year period.

According to Peyton, you should go easy on steak if you are looking to avoid a flare up.

She explained: "Whilst there are fats that send out anti-inflammatory messages, there are also fats that can create pro-inflammatory messages in the body. These typically come from animal fats."

"We all require the ability to create some inflammation when there is a need to heal (after an injury for example)."

However, as Peyton pointed out, the ratio of inflammatory fats is too high in the typical Western diet.

"Therefore take a look at your diet and assess whether you are consuming sufficient anti-inflammatory fats and not too many pro-inflammatory fats. It is all about the balance," she said.

According to the NHS, if you feel your arthritis is aggravated by eating certain foods, it may be useful to try avoiding problematic foods for a few weeks to see if your symptoms improve.

"But it's important to ensure your overall diet is still healthy and balanced," the healthy body says.

A Mediterranean-style diet, which is based on vegetables, fruits, legumes, nuts, beans, cereals, grains, fish and unsaturated fats such as olive oil, is recommended.

According to the NHS, there's some evidence to suggest that taking fish oil supplements may help reduce joint pain and stiffness caused by rheumatoid arthritis.

Eating a healthy diet can also help to maintain a healthy weight.

According to the National Rheumatoid Arthritis Society (NRAS), excess weight is bad for joints and overall health.

Original post:
Rheumatoid arthritis: The healthy bread alternative that could be making symptoms worse - Express

Photo credit: NBC - Getty Images

From Woman's Day

On Tuesday, Todays Al Roker announced he would be undergoing total shoulder replacement surgery. The NBC weatherman said hes been living with intense pain in his right shoulder due to arthritis, a general term for a range of conditions that cause swelling, pain, and stiffness in or around a joint.

According to the Centers for Disease Control and Prevention, 1 in 4 Americans have arthritis, and its typically treated with medication or surgery to repair the joint or manage symptoms.

The arthritis in Al's right shoulder has caused pain and affected his range of motion, particularly his ability to move his shoulder up and down. Its not bad during the day, but at night its an intense pain that literally wakes me up. For the last month, Ive only been sleeping about two or three hours a night, which even for me is a little bit less, Al said on the 3rd hour of Today. Its gotten to the point where I cant even sleep at night.

Al, who said his moms side of the family suffers from really intense arthritis, has osteoarthritis, the most common form of the condition. Osteoarthritis occurs when the protective cartilage that cushions the bones begins to wear down over time, causing pain and joint damage.

The surgery will be Al's second shoulder surgery in six years, after he had his rotator cuff repaired in his left shoulder in 2014. The procedure also marks Rokers second procedure in less than a year, as the Today host had hip replacement surgery in September 2019. The deal is that Im going to have replaced everything by 2027, Al joked.

Al's doctor, Riley Williams III, M.D., an orthopedic surgeon at the Hospital for Special Surgery, told Today that the surgery is designed to restore the normal joint services so that arthritic, achy pain that hes been having and waking him up at night can go away, and we can kind of get him back on a road to recovery.

Story continues

What you can expect after having a shoulder replacement is 25-plus years of really good function, provided you do all the requisite things after surgery [like] getting good healing, good nutrition and physical therapy to re-strengthen the muscles around the shoulder, Williams added. It really, really is life-changing and can bring you back to a point where you dont even realize that you had the shoulder operated on in the first place.

Al will not host Today this week as he recovers, and he will likely be in a sling for the next three weeks. He will also undergo physical therapy in the days after his procedure.

Want more entertainment news? You're in luck! Sign up for our FREE newsletter for even more of the Woman's Day content you want.

You Might Also Like

See the original post here:
Al Roker Will Have Total Shoulder Replacement Surgery Due to Intense Arthritis Pain - Yahoo Lifestyle

Here are the top stories recently covered by DocWire News in the rheumatology section. In this edition, read about the effect of rheumatic diseases on COVID-19 severity, virtual computer-assisted preoperative planning in hip fracture, racial disparities in psoriatic arthritis, and fatigue in rheumatic diseases.

Hospitalized COVID-19 patients with connective tissue diseases may be at risk for increased illness severity, according to a recent study, but inflammatory arthritis (IA) may not have the same effect. Final analysis included 456 patients each in rheumatic and non-rheumatic groups. In the rheumatic disease cohort, 60% of patients had IA, and 40% had connective tissue disease. About three-quarters of patients (74%) were hospitalized. The risk of severe COVID-19 was 31.6% in the rheumatic cohort and 28.1% in the non-rheumatic cohort. In bivariate analysis, factors associated with increased COVID-19 severity risk in the rheumatic group were aging; male sex; and previous comorbidity including obesity, diabetes, hypertension, or cardiovascular or lung disease. Upon logistic regression analysis, the factors independently associated with severe COVID-19 disease were increased age, male sex, and connective tissue disease.

An estimated 300,000 hip fractures occur in the U.S. each yeara number that is expected to double with the aging population. About half of hip fractures are intertrochanteric fractures, but postoperative outcomes tend to be poor, including a high risk of mortality as well as poorer functional and quality of life outcomes. Certain risk factors for such poor outcomes are age and sexwhich cannot be modified. One thing that can be modified, though, is preoperative planning. And according to a study, computer-assisted virtual planning in cases of intertrochanteric hip fracture may improve postoperative complications, including mortality risk.

A study observed how ethnicity may affect disease expression of psoriatic arthritis (PsA), observing differences between patients of South Asian (SA) versus North European (NE) descent. They concluded that SA patients may have poorer clinical outcomes and be more adversely affected by PsA disease than NE patients.

IA patients often experience fatigue; 41% to 51% of rheumatoid arthritis, PsA, and spondyloarthritis patients suffer from severe fatigue. Patients with these rheumatic diseases who are plagued by fatigue may suffer in several domains, including quality of life, work impairment, depression, and more, according to a new study.

Here is the original post:
Rheum Round-up: Rheumatic Disease and COVID-19 Severity, Improving Hip Fracture Outcomes, and more - DocWire News

Hospitalized COVID-19 patients with connective tissue diseases may be at risk for increased illness severity, according to a recent study, but inflammatory arthritis may not have the same effect.

Since severe COVID-19 is associated with a hyperinflammatory process, it is of particular interest to investigate how pre-existing inflammatory diseases or the previous use of immunosuppressive agents influence COVID-19 expression, the study authors explained.

The researchers identified PCR+COVID-19 rheumatic patients with chronic inflammatory arthritis (including rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis) or connective tissue diseases (including systemic lupus erythematosus, Sjgrens syndrome, systemic sclerosis, polymyalgia rheumatica, and vasculitides) and compared them 1:1 to non-rheumatic controls matched based on age, sex, and PCR date. The primary outcome was severe COVID-19 (death, invasive ventilation, intensive care unit admission, or serious complications). The correlation between severe COVID-19 and potential prognostic variables was evaluated, adjusting for COVID-19 treatment.

Final analysis included 456 patients each in the rheumatic and non-rheumatic groups. Both cohorts had a mean ae of 63 years and were 41% male. In the rheumatic disease cohort, 60% of patients had inflammatory arthritis, and 40% had connective tissue disease. About three-quarters of patients (74%) were hospitalized. The risk of severe COVID-19 was 31.6% in the rheumatic cohort and 28.1% in the non-rheumatic cohort. In bivariate analysis, factors associated with increased COVID-19 severity risk in the rheumatic group were aging; male sex; and previous comorbidity including obesity, diabetes, hypertension, or cardiovascular or lung disease. Upon logistic regression analysis, the factors independently associated with severe COVID-19 disease were increased age (odds ratio [OR]=4.83; 95% confidence interval [CI], 2.78 to 8.36), male sex (OR=1.93; 95% CI, 1.21 to 3.07), and connective tissue disease (OR=1.82; 95% CI, 1.00 to 3.30).

The researchers stated in their conclusion that among hospitalised patients with inflammatory rheumatic diseases, having a [connective tissue disease] pose[s] a significantly greater risk for poor outcomes, whereas immunosuppressive therapies do not. Previously known risk factors as ageing and male sex also apply to patients with rheumatic diseases. This observation should help to tailor recommendations to specific diagnostic and therapeutic groups of patients with rheumatic diseases during this or future coronavirus pandemics.

The study was published in Annals of the Rheumatic Diseases.

Read more here:
Do Inflammatory and Autoimmune Rheumatic Diseases Affect COVID-19 Illness Severity? - DocWire News

A model incorporating gene expression and clinical factors predicts response to anti-tumor necrosis factor (TNF) therapy in patients with rheumatoid arthritis (RA), according to study results published in Network and Systems Medicine.

Rheumatoid arthritis is a complex disease and the molecular factors that predict response to treatment are poorly understood. Using gene expression data from patients receiving anti-TNF therapy, investigators aimed to build a biomarker panel, which predicts response to anti-TNF therapies in patients with RA.

Using publicly available data, a comprehensive map of the human protein-protein interactome was generated and used to identify an RA disease module, which contained approximately 200 proteins. Within this module, 66% of the proteins had been previously linked to RA in genome-wide association studies, and the remaining were significantly enriched in similar Gene Ontology biological processes.

Microarray data were obtained from the Gene Expression Omnibus database for 58 women receiving anti-TNF therapy. Using a random forest machine-learning algorithm, the data were used to identify genes for which expression was predictive of response and nonresponse to therapy. Based on the microarray profile and the RA disease module, 37 genes were identified as discriminatory biomarkers for anti-TNF response.

In addition, RNA sequencing (RNAseq) data were obtained for 143 patients with RA from the Comparative Effectiveness Registry to Study Therapies for Arthritis and Inflammatory Conditions (CERTAIN) study. In addition to gene expression, RNAseq data enabled the identification of single-nucleotide variations (SNVs; formerly single-nucleotide polymorphisms) that were associated with treatment response. An additional 22 SNVs, which were associated with the RA disease model, were identified that were linked to response to anti-TNF therapy.

With the inclusion of clinical factors, a total of 70 biomarkers were identified and used to train a machine-learning algorithm to predict response to anti-TNF therapy. The final model generated, which predicted nonresponse to anti-TNF therapy, consisted of 10 SNPs, 8 gene transcripts, 2 laboratory tests, and 3 clinical measures.

To confirm that the model was broadly generalizable, data from an independent group of 175 patients from the CERTAIN study were used for a validation trial. Patients who were identified by the model as being nonresponders to anti-TNF therapy were 6.57-times more likely to be a true nonresponder than a responder (95% CI, 2.75-15.70). The model predicted nonresponse to therapy with a positive predictive value of 89.7% (95% CI, 79.0-95.7%), a specificity of 86.8% (95% CI, 72.4-94.1%), and a sensitivity of 50.0% (95% CI, 40.8-58.7%). There was no significant difference observed in the predictive power of the model based on ethnicity.

When the relevant gene transcripts and SNVs were mapped to the human interactome, they were all within close proximity to the RA disease module as well as established RA drug targets, including Janus kinase and TNF-. Pathway enrichment identified genes involved in T-cell signaling as the most enriched pathway in the biomarkers associated with a therapeutic response.

Customization of treatment regimens to match the individualized disease biology of each patient is a goal of modern medicine, the researchers concluded. Development and validation of a drug response algorithm that predicts nonresponse to a targeted therapy using this machine-learning and network medicine approach show great promise for advancing precision medicine in the treatment of RA and other complex autoimmune diseases where costly therapeutic interventions are met with inadequate patient response.

Disclosure: This study was supported by Scipher Medicine Corporation. Please see the original reference for a full list of authors disclosures.

Mellors T, Withers JB, Ameli A, et al. Clinical validation of a blood-based predictive test for stratification of response to tumor necrosis factor inhibitor therapies in rheumatoid arthritis patients. Network and Systems Medicine. 2020;3(1):91-104.

Continue reading here:
Clinically Validated Blood-Based Test Predicts Response to Anti-TNF Therapies in RA - Rheumatology Advisor

Tulsi or holy basil is loaded with several health benefits. You can prepare tulsi tea to fight various ailments. Read here to know some notable health benefits of drinking tulsi tea.

Drinking tulsi tea can help you boost immunity

Holy basil or tulsi is a part of almost every Indian household. This auspicious plant is loaded with several amazing health benefits too. Holy basil has a strong taste and aroma and can be added to your diet in several ways. One of the healthiest ways to add holy basil to your diet is by preparing tulsi tea. If you are a tea lover, you should definitely try tulsi tea to reap the health benefits these leaves can offer. If you are curious to know the benefits of tulsi tea, keep reading to know these.

Tulsi tea has a positive effect on your mental health. Drinking this tea leaves a soothing effect that can help you relieve stress. Studies also suggest that it can help you control symptoms of anxiety.

Drinking tulsi tea can help you beat stress effectivelyPhoto Credit: iStock

Holy basil helps in controlling inflammation and joint pain. These are the two common symptoms of arthritis. Therefore, drinking tulsi tea can help in controlling arthritis symptoms.

Also read:Arthritis Diet: Foods You Should Avoid To Control Inflammation

Tulsi leaves are loaded with anti-microbial properties which can help you promote overall oral health. This tea can help control harmful bacteria and germs in the mouth.

Studies suggest that tulsi is beneficial in controlling blood sugar levels and other symptoms of type-2 diabetes.

Also read:Diabetes Diet: Know How Many Almonds You Should Eat To Lower Blood Sugar Levels

Bad cholesterol levels are linked with a higher risk of heart disease. Adding tulsi to your diet can help in controlling bad cholesterol levels.

Tulsi tes is beneficial for your heart health as it helps control cholesterol levelsPhoto Credit: iStock

Tulsi is one of the herbs which can help you boost immunity. Aa sting immunity system will help you fight against illness effectively.

Preparing tulsi tea is quite simple. You can boil some tulsi leaves in one to two cups of water. Add ginger to enhance the taste of the tea. Boil the mixture properly. After some time, strain the tea and add lemon and honey to enhance the taste.

Promoted

Also read:How Many Cups Of Green Tea Should You Drink Per Day? Know The Side Effects Of Drinking Too Much Green Tea

Disclaimer: This content including advice provides generic information only. It is in no way a substitute for qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.

DoctorNDTV is the one stop site for all your health needs providing the most credible health information, health news and tips with expert advice on healthy living, diet plans, informative videos etc. You can get the most relevant and accurate info you need about health problems like diabetes, cancer, pregnancy, HIV and AIDS, weight loss and many other lifestyle diseases. We have a panel of over 350 experts who help us develop content by giving their valuable inputs and bringing to us the latest in the world of healthcare.

Read more:
Holy Basil: Know The Many Health Benefits Of Drinking Tulsi Tea - Doctor NDTV

The Rheumatoid Arthritis Diagnosis Tests market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Our analysts monitoring the situation around the Globe explain that after COVID-19 crisis the market will generate remunerative prospects for producers. The goal of the report is to provide a further illustration of the current scenario, economic slowdown and effect of COVID-19 on the industry as a whole.

Global Rheumatoid Arthritis Diagnosis Tests Market is valued at USD 529.4 Million in 2018 and expected to reach USD 822.7 Million by 2025 with a CAGR of 6.5% over the forecast period. Increasing geriatric population globally is anticipated to drive growth of Global Rheumatoid Arthritis Diagnosis Tests Market.

Rheumatoid arthritis is a long-term, progressive and disabling autoimmune disease (as in this condition a persons immune system mistakes the bodys healthy tissues for foreign invaders). It is also a systemic disease, which means it affects the whole body. It causes inflammation, swelling, and pain in and around the joints and other body organs. It most commonly affects the hands and feet first, but it can occur in any joint. Its major symptoms includes; pain, swelling, and stiffness in more than one joint, symmetrical joint involvement, joint deformity, unsteadiness when walking, a general feeling of being unwell, fever, loss of function and mobility, weight loss, weakness and others. There are several different types of rheumatoid arthritis, some of them are seropositive RA, seronegative RA and JIA (juvenile idiopathic arthritis). It affects adults of any age, although most people are diagnosed between the ages of 40 and 60 and it is two to three times more common among women than men. A diagnosis of rheumatoid arthritis is based on the patients symptoms, a physical examination and the results of x-rays, scans and blood tests.

Global rheumatoid arthritis diagnosis tests market report is segmented on the basis of type, end-user and region & country level. Based upon type, global rheumatoid arthritis diagnosis tests market is classified into serology tests and monitoring rheumatoid arthritis treatment efficiency tests. The serology tests segment is further categorized into erythrocyte sedimentation rate, anti-cyclic citrullinated peptide, rheumatoid factor, antinuclear antibody, uric acid and others. The monitoring rheumatoid arthritis treatment efficiency tests segment is further categorized into muscle enzyme tests, salicylate level count and creatinine test. Based upon end-user, global rheumatoid arthritis diagnosis tests market is divided into hospitals, diagnostics laboratories and ambulatory surgical centers.

The regions covered in this Rheumatoid Arthritis Diagnosis Tests Market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, the market of rheumatoid arthritis diagnosis tests is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, Middle East Asia (UAE, Saudi Arabia, Egypt) GCC, Africa, etc.

Scope Of The Report:Report evaluates the growth rate and the Market value based on Market dynamics, growth inducing factors. The complete knowledge is based on latest industry news, opportunities and trends. The report contains a comprehensive Market analysis and vendor landscape in addition to a SWOT analysis of the key vendors.Geographically, this report split global into several key Regions, revenue (Million USD) The geography (North America, Europe, Asia-Pacific, Latin America and Middle East & Africa) focusing on key countries in each region. It also covers market drivers, restraints, opportunities, challenges, and key issues in Global Rheumatoid Arthritis Diagnosis Tests Market.

Key Benefits for Rheumatoid Arthritis Diagnosis Tests Market Reports Global market report covers in-depth historical and forecast analysis. Global market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, Regional and Country Level. Global market report helps to identify opportunities in market place. Global market report covers extensive analysis of emerging trends and competitive landscape.

Rheumatoid Arthritis Diagnosis Tests Market Segmentation:By Type: Serology Tests o Erythrocyte Sedimentation rate o Anti-Cyclic Citrullinated Peptide o Rheumatoid Factor o Antinuclear Antibodyo Uric Acido Others Monitoring Rheumatoid Arthritis Treatment Efficiency Tests o Muscle Enzyme Tests o Salicylate Level Counto Creatinine TestBy End-User: Hospitals Diagnostics Laboratories Ambulatory Surgical Centers By Region North Americao U.S.o Canadao Mexico Europeo UKo Franceo Germanyo Russiao Rest of Europe Asia-Pacifico Chinao South Koreao Indiao Japano Rest of Asia-Pacific LAMEAo Latin Americao Middle Easto Africa

Rheumatoid Arthritis Diagnosis Tests Market Key Players:Antibodies Inc.Euro Diagnostica ABQiagen NVSiemens Healthcare GmbHBio Rad Laboratories Inc.Genway Biotech, Inc.Abbott DiagnosticsBeckman Coulter, Inc.F. Hoffmann-La Roche Ltd.Thermo Fisher Scientific Incothers.

This comprehensive report will provide: Enhance your strategic decision making Assist with your research, presentations and business plans Show which emerging market opportunities to focus on Increase your industry knowledge Keep you up-to-date with crucial market developments Allow you to develop informed growth strategies Build your technical insight Illustrate trends to exploit Strengthen your analysis of competitors Provide risk analysis, helping you avoid the pitfalls other companies could make Ultimately, help you to maximize profitability for your company.Our Market Research Solution Provides You Answer to Below Mentioned Question: Which are the driving factors responsible for the growth of market? Which are the roadblock factors of this market? What are the new opportunities, by which market will grow in coming years? What are the trends of this market? Which are main factors responsible for new product launch? How big is the global & regional market in terms of revenue, sales and production? How far will the market grow in forecast period in terms of revenue, sales and production? Which region is dominating the global market and what are the market shares of each region in the overall market in 2017? How will each segment grow over the forecast period and how much revenue will these segment account for in 2025? Which region has more opportunities?

Table of Content1 Study Coverage1.1 Rheumatoid Arthritis Diagnosis Tests Product1.2 Key Market Segments in This Study1.3 Key Manufacturers Covered1.4 Market by Type1.5 Market by Application1.6 Study Objectives1.7 Years Considered

2 Executive Summary2.1 Global Rheumatoid Arthritis Diagnosis Tests Market Size2.1.1 Global Rheumatoid Arthritis Diagnosis Tests Revenue 2014-20252.1.2 Global Rheumatoid Arthritis Diagnosis Tests Production 2014-20252.2 Rheumatoid Arthritis Diagnosis Tests Growth Rate (CAGR) 2020-20252.3 Analysis of Competitive Landscape2.3.1 Manufacturers Market Concentration Ratio2.3.2 Key Rheumatoid Arthritis Diagnosis Tests Manufacturers2.3.2.1 Rheumatoid Arthritis Diagnosis Tests Manufacturing Base Distribution, Headquarters2.3.2.2 Manufacturers Rheumatoid Arthritis Diagnosis Tests Product Offered2.3.2.3 Date of Manufacturers Enter into Rheumatoid Arthritis Diagnosis Tests Market2.4 Key Trends for Rheumatoid Arthritis Diagnosis Tests Markets & Products

3 Market Size by Manufacturers3.1 Rheumatoid Arthritis Diagnosis Tests Production by Manufacturers3.1.1 Rheumatoid Arthritis Diagnosis Tests Production by Manufacturers3.1.2 Rheumatoid Arthritis Diagnosis Tests Production Market Share by Manufacturers3.2 Rheumatoid Arthritis Diagnosis Tests Revenue by Manufacturers3.2.1 Rheumatoid Arthritis Diagnosis Tests Revenue by Manufacturers (2014-2020)3.2.2 Rheumatoid Arthritis Diagnosis Tests Revenue Share by Manufacturers (2014-2020)3.3 Rheumatoid Arthritis Diagnosis Tests Price by Manufacturers3.4 Mergers & Acquisitions, Expansion Plans

4 Rheumatoid Arthritis Diagnosis Tests Production by Regions4.1 Global Rheumatoid Arthritis Diagnosis Tests Production by Regions4.1.1 Global Rheumatoid Arthritis Diagnosis Tests Production Market Share by Regions4.1.2 Global Rheumatoid Arthritis Diagnosis Tests Revenue Market Share by Regions4.2 North America4.2.1 North America Rheumatoid Arthritis Diagnosis Tests Production4.2.2 North America Rheumatoid Arthritis Diagnosis Tests Revenue4.2.3 Key Players in North America4.2.4 North America Rheumatoid Arthritis Diagnosis Tests Import & Export4.3 Europe4.3.1 Europe Rheumatoid Arthritis Diagnosis Tests Production4.3.2 Europe Rheumatoid Arthritis Diagnosis Tests Revenue4.3.3 Key Players in Europe4.3.4 Europe Rheumatoid Arthritis Diagnosis Tests Import & Export4.4 China4.4.1 China Rheumatoid Arthritis Diagnosis Tests Production4.4.2 China Rheumatoid Arthritis Diagnosis Tests Revenue4.4.3 Key Players in China4.4.4 China Rheumatoid Arthritis Diagnosis Tests Import & Export4.5 Japan4.5.1 Japan Rheumatoid Arthritis Diagnosis Tests Production4.5.2 Japan Rheumatoid Arthritis Diagnosis Tests Revenue4.5.3 Key Players in Japan4.5.4 Japan Rheumatoid Arthritis Diagnosis Tests Import & Export

5 Rheumatoid Arthritis Diagnosis Tests Consumption by Regions5.1 Global Rheumatoid Arthritis Diagnosis Tests Consumption by Regions5.1.1 Global Rheumatoid Arthritis Diagnosis Tests Consumption by Regions5.1.2 Global Rheumatoid Arthritis Diagnosis Tests Consumption Market Share by Regions5.2 North America5.2.1 North America Rheumatoid Arthritis Diagnosis Tests Consumption by Application5.2.2 North America Rheumatoid Arthritis Diagnosis Tests Consumption by Countries5.2.3 United States5.2.4 Canada5.2.5 Mexico5.3 Europe5.3.1 Europe Rheumatoid Arthritis Diagnosis Tests Consumption by Application5.3.2 Europe Rheumatoid Arthritis Diagnosis Tests Consumption by Countries5.3.3 Germany5.3.4 France5.3.5 UK5.3.6 Italy5.3.7 Russia5.4 Asia Pacific5.4.1 Asia Pacific Rheumatoid Arthritis Diagnosis Tests Consumption by Application5.4.2 Asia Pacific Rheumatoid Arthritis Diagnosis Tests Consumption by Regions5.4.3 China5.4.4 Japan5.4.5 South Korea5.4.6 India5.4.7 Australia5.4.8 Indonesia5.4.9 Thailand5.4.10 Malaysia5.4.11 Philippines

About Us: Brandessence Market Research and Consulting Pvt. ltd.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Contact us at: +44-2038074155 or mail us at [emailprotected]

Blog: https://businessstatsnews.com

Blog: http://www.dailyindustrywatch.com

Blog: https://marketsize.biz

Blog: https://technologyindustrynews.com

Blog: https://marketstatsreport.com

Top Trending Reports:

https://www.1077yesfm.com/story/42489057/contact-center-software-market-size-shares-and-strategies-for-key-industry-players-by-2025

https://www.1077yesfm.com/story/42489058/coal-bed-methane-market-size-top-key-players-g3-exploration-igas-energy-great-eastern-energy-corporation-ltd-black-diamond-energy-inc-oil-and-natural

https://www.1077yesfm.com/story/42489055/smart-agriculture-market-size-by-top-key-players-deere-company-trimble-agco-agjunction-raven-industries-delavai-ag-leader-technology

https://www.1077yesfm.com/story/42489111/offshore-wind-energy-market-foreseen-to-grow-exponentially-over-forecast-2020-2025-bmrc

Top Trending Reports:

https://www.marketwatch.com/press-release/continuous-glucose-monitoring-market-size-share-cgm-market-analysis-and-forecast-2025-2020-08-12?tesla=y

https://www.marketwatch.com/press-release/global-data-center-market-size-share-2019-analysis-segmentation-market-scenario-and-forecast-to-2025-2020-08-12?tesla=y

https://www.marketwatch.com/press-release/bug-bounty-platforms-market-size-global-trends-market-share-and-market-forecast-2020-to-2027-2020-08-12?tesla=y

https://www.marketwatch.com/press-release/global-body-contouring-market-size-growth-shares-challenges-opportunities-and-forecast-to-2025-2020-08-12?tesla=y

https://www.marketwatch.com/press-release/blood-plasma-products-market-size-share-key-players-trends-detailed-analysis-and-forecast-to-2025-2020-08-12?tesla=y

Go here to read the rest:
Rheumatoid Arthritis Diagnosis Tests Business opportunity 2020 Sales Revenue Analysis, Major Manufacturers Performance, Industry Share and Forecast...

Methotrexate (MTX) monotherapy may be insufficient for achieving sustained minimal disease activity in patients with psoriatic arthritis (PsA), according to study data published in RMD Open. In a cohort of patients with PsA who were initiated with MTX, only 18% maintained minimal disease activity over 1 year of treatment. Methotrexate nonresponders vs responders were more likely to have interleukin (IL)-23-driven disease.

Investigators abstracted data from the Dutch Southwest Early Psoriatic Arthritis Cohort (DEPAR) study collected between 2013 and 2018. The DEPAR enrollees with oligoarthritis or polyarthritis who had 1 year of follow-up data were eligible for inclusion in the study. According to the DEPAR protocol, patients provided clinical data and blood samples before treatment initiation and every 3 months thereafter. Minimal disease activity was defined according to the following parameters: swollen and tender joint counts 1; Leeds Enthesitis Index 1; Psoriasis Area Severity Index 1; patients global assessment by visual analog scale (VAS) 20 mm; patients pain assessment by VAS 15 mm; and Health Assessment Questionnaire 0.5. Serum cytokine concentrations were determined at baseline, 3 months, and 6 months using a bead-based immunoassay.

The study cohort included 219 patients (50% men), with mean age at enrollment of 5314 years. Overall, 183 patients (84%) were initiated with MTX monotherapy within 6 months of PsA diagnosis, of whom 49% remained on MTX monotherapy for 1 year. A total of 44 patients (24%) reached minimal disease activity at 6 months. At 1 year, 33 patients (18%) remained in minimal disease activity.

Compared with patients who had minimal disease activity at 1 year, patients who did not respond to treatment with MTX had higher mean baseline concentrations of IL-23 (17.444.78 vs 62.9425.02), tumor necrosis factor (2.630.66 vs 7.832.79), granulocyte-macrophage colony-stimulating factor (2.780.64 vs 6.52.07), interferon gamma (6.671.29 vs 19.746.85), and IL-10 (1.030.13 vs 2.080.6; all P <.05). Concentrations of IL-10 and IL-23 remained significantly higher among nonresponders at 6 months.

In this observational care cohort of patients with PsA, only 18% who were initiated on MTX remained in minimal disease activity at 1 year. Higher baseline and follow-up concentrations of IL-23 and IL-10 were observed in nonresponders. Further study is necessary to confirm the validity of these biomarkers for MTX response.

Study limitations included potential confounding factors and the need to validate the use of serum IL-23 as a therapy-response biomarker. Overall, conclusions about the effect of MTX therapy must be drawn with caution.

This study highlights the potential value of use of new tools, such as measuring cytokine profiles, to stratify patients for underlying driving pathogenic mechanisms of their disease, the investigators concluded.

den Braanker H, Wervers K, Mus AMC, et al. Achieving sustained minimal disease activity with methotrexate in early interleukin 23-driven early psoriatic arthritis. RMD Open. 2020;6(2):e001175.

Follow this link:
Evaluating Methotrexate Monotherapy for Minimal Disease Activity Achievement in Early PsA - Rheumatology Advisor

August 16, 2020

Vision scientist David Williams is third consecutive recipient with Rochester ties.

For the third consecutive year, a member of the Rochester community has been recognized by the Association of University Professors of Ophthalmology (AUPO) for outstanding vision research.

David Williams, the William G. Allyn Professor of Medical Optics, has been selected by the association as the 2021 recipient of the RPB David F. Weeks Award for Outstanding Vision Research. The award annually recognizes and celebrates an outstanding ophthalmic vision scientist whose research has made meaningful contributions to the understanding or treatment of potentially blinding eye diseases.

The previous two recipients of the award were:

2020: Christine Curcio 81 (PhD), who is now the White-McKee Endowed Professor in Ophthalmology at the University of Alabama and director of the Age-Related Macular Degeneration Histopathology Lab.

2019: Jayakrishna Ambati 98M (Res), who is now a professor of ophthalmology at the University of Virginia.

Williams, who holds joint appointments in optics, brain and cognitive sciences, ophthalmology, and biomedical engineering, is widely regarded as one of the worlds leading experts on human vision. As a pioneer in using new technologies that improve the eyesight of people around the world, he and his research team demonstrated the first adaptive optics system for the eye, making it possible to image individual retinal cells. The techniques developed by Williams and his group have also improved vision in patients with contact lenses, intraocular lenses, and laser refractive surgery. For example, the methods Williamss group developed are used in many of the Lasik procedures conducted worldwide today.

Williams additionally serves as director of the Center for Visual Science, a research program consisting of more than 37 faculty members from seven different departments dedicated to understanding how humans see, as well as the disorders that compromise sight.

Williams joined the Rochester faculty in 1981, and served as dean for research in Arts, Sciences & Engineering from 2011 to 2019. He is a fellow of the Association for Research in Vision and Ophthalmology, the Optical Society of America, and the American Association for the Advancement of Science. In 2017, he was named a member of the National Academy of Sciences.

The Weeks Award is scheduled to be presented to Williams at the AUPO Annual Meeting in February 2021.

Tags: Center for Visual Science, David Williams, Department of Biomedical Engineering, Department of Brain and Cognitive Sciences, Department of Ophthalmology, Hajim School of Engineering and Applied Sciences, Institute of Optics

Category: University News

See original here:
Rochester researcher recognized with national award for outstanding vision research - University of Rochester

Itchiness, tiredness and sometimes burning sensation in the eyes can be a sign of eyestrain. Too much exposure to screen is one of the leading causes of eyestrain. Here are some tips you can follow to prevent this.

Exposure to screens for too long can negatively affect your eyes in several ways

When at home, you tend to spend more time staring at the screens. Too much exposure leads to several harmful effects. Eyestrain is a common condition in this digital age. Eye strain can irritate the eyes, headaches, blurry vision, dry eye, pain in neck, shoulder and back, excessive stress, poor vision and trouble in focusing. This condition can also be a result of driving for long-distance as it can make your eyes tired. But the use of digital gadgets is one of the leading causes. If left uncontrolled eye strain can lead to several problems like macular degeneration, sleep disturbances and in some cases cataract.

Eyestrain can causes discomfort in performing day to day activities too. Here are some tips you can follow to prevent this condition.

It is usually advised to take a 20 seconds break after continuous exposure to screens for 20 mins. Try to create a balance between your work and breaks so that your eyes get enough rest.

Take frequent breaks to give your eyes a break from the screenPhoto Credit: iStock

While working or watching something do not keep the screen to close to your eyes. Ideally, it is advised to keep a minimum distance of 20 inches between the screen and your eyes.

Also read:Eye Care: 6 Best Tips You Need

Not just the distance you should also maintain the right angle of the placement of the screen. Keep the screen at the level of your eyes or slightly below. It should not be above the eye level or too low (staring at low level can lead to text neck).

These days a variety of lenses are available. You can consult an eye specialist to get the perfect glasses for your eyes. Different lenses have different coatings and tints.

Also read:5 Nutrients You Should Not Miss To Maintain Healthy Eyesight

You should also describe other discomforts you are facing while working. Many experience irritation or dry eye. Your doctor may prescribe eye drops to address the issues.

Use eye drop if required to fight discomfortPhoto Credit: iStock

When you are working, you take a break and start using your phone. In this process, you do not give your eye the required break. During a break make sure that you do not use any kind of screens.

Promoted

Also read:How To Manage Dry Eyes Naturally?

Disclaimer: This content including advice provides generic information only. It is in no way a substitute for qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.

DoctorNDTV is the one stop site for all your health needs providing the most credible health information, health news and tips with expert advice on healthy living, diet plans, informative videos etc. You can get the most relevant and accurate info you need about health problems like diabetes, cancer, pregnancy, HIV and AIDS, weight loss and many other lifestyle diseases. We have a panel of over 350 experts who help us develop content by giving their valuable inputs and bringing to us the latest in the world of healthcare.

Originally posted here:
Experiencing Eye Strain Too Often? Here Are Some Prevention Tips That Might Help - Doctor NDTV

He wasn't going to let losing his sight stop him doing the Great North Run.

So this dedicated runner certainly isn't going to let a pandemic get in the way.

The Great North Run may have been cancelled as a result of Covid-19, but Gary Ferguson, from Rowlands Gill, is among the hundreds of people who are finding a new way to test their bodies and raise money for charity, just as they planned to do in the famous half marathon.

Civil servant Gary, 59, has reached the finish line of the famous Newcastle - South Shields course around 13 times before, but this year was set to be an extra challenge.

Though he's had serious eye problems for most of his life, this was to be his first time completing the run since he eyesight deteriorate to the point where he could no longer run safely without a guide, and has applied for a guide dog.

Undeterred, Gary, who is registered blind, decided to raise cash for others in his position, running to collect sponsorship for the Guide Dogs charity, as well as the NHS.

He's now completing the Great North Run solo challenge instead: completing 40 runs over the 78 days leading up to September 13, when the half marathon should have taken place.

On the day itself, Gary and his guide runner, Craig Merrick, will be running 13.1miles along the Derwent Walk from Rowlands Gill, with Gary in a 'Braveheart' costume, an outfit he's often used in the Great North Run.

He said: "It would have been the first time I'd run it with my eyes this bad, and I was looking forward to it, because having applied for a guide dog myself I wanted to get the chance to support and raise money for them.

"It was disappointing when Covid-19 knocked it all back: it's frustrating for everybody who was going to run, but it's the charities who really suffer, because they are losing millions that they would have got in sponsorship."

Running while blind is not without its challenges, and Gary has been forced to adapt to a whole new way of doing the sport he loves, due to the cloudy cornea which makes the world around him dark and his vision 'like being in a steamy sauna'.

"It's frustrating, more than anything. Usually I like to dictate the pace, but now I have to run right behind my guide: they run right in front of me wearing a high-visibility tabard and that's about as far as I can see," he explained.

"Sometimes, depending on the weather, if the sun is shining through the trees, for example, the person I'm running behind tends to disappear, so some of the time I am literally running blind, hoping there's nothing going to hit me before that little bit of visibility comes back."

He's spurred on by his love of running outdoors, as well as a desire to help others who've lost their sight, as he knows from experience how valuable a guide dog can be.

He said: "I've been approved for a dog and I'm on a waiting list, but it's a long list because there are a lot of people needing it.

"It's about independence: at the moment I'm having to depend on other people for small things, like going to the shops, with a dog, I could do that on my own."

Gary is raising money for Guide Dogs and the NHS at https://justgiving.com/fundraising/gary-ferguson6

Read more here:
Blind Gateshead runner won't let sight loss or the pandemic stop him completing the Great North Run - Chronicle Live

DUBLIN--(BUSINESS WIRE)--The "Phoropters Market - Growth, Trends, and Forecast (2020-2025)" report has been added to ResearchAndMarkets.com's offering.

The global Phoropters market is anticipated to grow with a CAGR of nearly 4.1%, during the forecast period.

Certain factors that are driving the market growth include growing prevalence and recurrence of eye disorders and technological advancements.

In many developed and developing nations, eye disorders have emerged as potential threats to the status of sight of their people. The significant rise in the prevalence of diabetes in various countries has led to diabetic retinopathy being added to the priority list.

According to the WHO, in 2018, it was estimated that approximately 1.3 billion people were living with some form of vision impairment, 188.5 million people had mild vision impairment, 217 million had moderate to severe vision impairment, and 36 million people are blind.

Across the globe, the leading causes of vision impairment are uncorrected refractive errors and cataracts, and most people with vision impairment are over the age of 50 years. As per the WHO, chronic eye diseases are the number one cause of vision loss, with the top two causes being unoperated cataracts and uncorrected refractive errors. The former is the leading cause in countries with low- or middle-incomes.

In addition, the global geriatric population continues to grow at an unprecedented rate. The increase in the aging population presents several public health challenges that people need to prepare for. Presbyopia is an age-related visual impairment. It results from the gradual decrease in accommodation expected with age and can have multiple effects on quality of vision and quality of life. Though not incapacitating if corrected, presbyopia without optical correction results in an inability to perform once-effortless near tasks at a customary working distance without experiencing visual symptoms.

Hence, the rising incidence of eye-related disorders is projecting a great impact on the growth of market studied.

Key Market Trends

Specialty Clinics Hold Significant Share

Specialty clinics are expected to observe a steady growth in adoption rate of phoropters, owing to the increasing number of eye disorders. For instance, the prevalence of presbyopia is higher in societies in which larger proportions of the population survive into old age. With the aging of the U.S. population, unprecedented number of patients with presbyopia can be expected to present to optometrists' offices in the coming years.

Because presbyopia is age related, its prevalence is directly related to the proportion of older persons in the population. Although it is difficult to estimate the incidence of a chronic condition such as presbyopia, due to its slow onset, it appears that the highest incidence of presbyopia (i.e., first-reported effects) is in people aged 42 to 44 years. Hence, with the emergence of such diseases, specialty clinics are gaining attention in the market studied.

North America Dominates the Global Market

In the North American region, the United States accounted for the largest market share. According to the 2018 report of the American Optometric Association, Myopia affects nearly 30 percent of the U.S. population.

While the exact cause of myopia is unknown, there is significant evidence that many people inherit myopia, or at least the tendency to develop myopia. If one or both parents are nearsighted, there is an increased chance their children will be nearsighted.

A study conducted for the year 2016-2017 estimated that 9.6 million adults in the United States are highly myopic, or severely nearsighted. Of those, nearly 820,000 have a degenerative form of the disease and more than 41,000 suffer a complication called myopic choroidal neovascularization that could cause long-term vision loss, with women at higher risk. The findings were published in the Journal of the American Academy of Ophthalmology.

Competitive Landscape

The global Phoropters market is moderately competitive and consists of a few major players. There is a presence of local as well as international companies in the global market. Some of the key players include Briot USA Inc., Huvitz Co. Ltd., Marco, Nidek, Reichert Inc., Rexxam Co. Ltd., Carl Zeiss AG, among others.

Key Topics Covered

1 INTRODUCTION

1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Growing Prevalence and Recurrence of Eye Disorders

4.2.2 Technological Advancements

4.3 Market Restraints

4.3.1 High Installation Cost and Lack of Skilled Optometrists

4.4 Porter's Five Force Analysis

5 MARKET SEGMENTATION

5.1 By Type

5.1.1 Manual

5.1.2 Digital

5.2 By End-user

5.2.1 Hospitals

5.2.2 Specialty Clinics

5.2.3 Others

5.3 Geography

5.3.1 North America

5.3.2 Europe

5.3.3 Asia-Pacific

5.3.4 Middle-East and Africa

5.3.5 South America

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

6.1.1 Briot USA Inc.

6.1.2 Huvitz Co. Ltd.

6.1.3 Marco

6.1.4 NIDEK Co. Ltd.

6.1.5 Reichert, Inc.

6.1.6 Rexxam Co. Ltd.

6.1.7 Righton Limited

6.1.8 Topcon Corporation

6.1.9 Carl Zeiss AG

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/k48c65

Read the original:
Global Phoropters Market Forecast 2020-2025 with Profiles of Major Players Briot USA, Huvitz, Marco, NIDEK, and Reichert Among Others -...

Bionic Eye Market

Los Angeles, United State,- This research study is one of the most detailed and accurate ones that solely focus on the global Bionic Eye market. It sheds light on critical factors that impact the growth of the global Bionic Eye market on several fronts. Market participants can use the report to gain a sound understanding of the competitive landscape and strategies adopted by leading players of the global Bionic Eye market. The authors of the report segment the globalBionic Eyemarket according to a type of product, application, and region. The segments studied in the report are analyzed on the basis of market share, consumption, production, market attractiveness, and other vital factors.

The geographical analysis of the global Bionic Eye market provided in the research study is an intelligent tool that interested parties can use to identify lucrative regional markets. It helps readers to become aware of the characteristics of different regional markets and how they are progressing in terms of growth. The report also offers a deep analysis of Bionic Eye market dynamics, including drivers, challenges, restraints, trends and opportunities, and market influence factors. It provides a statistical analysis of the global Bionic Eye market, which includes CAGR, revenue, volume, market shares, and other important figures. On the whole, it comes out as a complete package of various market intelligence studies focusing on the global Bionic Eye market.

Get PDF template of this report:https://www.qyresearch.com/sample-form/form/1537213/global-bionic-eye-market

Company Profiles: It is a very important section of the report that includes accurate and deep profiling of leading players of the global Bionic Eye market. It provides information about the main business, markets served, gross margin, revenue, price, production, and other factors that define the market progress of players studied in the Bionic Eye report.

Major Players Cited in the Report

Retina Implant AG, Bionic Vision Australia, THE BIONIC EYE, Pixium Vision, iBionics, Second Sight Medical Products, NeoStrata Company, ABIOMED, Berlin Heart, Zimmer Biomet, etc.

Global Bionic Eye Market Size Estimation

In order to estimate and validate the size of the global Bionic Eye market, our researchers used bottom-up as well as top-down approaches. These methods were also used to project the Bionic Eye market size of segments and sub-segments included in the report.

We used secondary sources to determine all breakdowns, splits, and percentage shares and completed their verification with the help of primary sources. We used both primary and secondary research processes to estimate the global Bionic Eye market size vis--vis value and analyze the supply chain of the industry. In addition, extensive secondary research was conducted to identify key players in the global Bionic Eye market.

Global Bionic Eye Market by Product

Electronic, Mechanical

Global Bionic Eye Market by Application

Hospitals, Clinics, Others Global Bionic Eye Market: Regional Analysis The report offers in-depth assessment of the growth and other aspects of the Bionic Eye market in important regions, including the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, Taiwan, Southeast Asia, Mexico, and Brazil, etc. Key regions covered in the report are North America, Europe, Asia-Pacific and Latin America. The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue, production, and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2015 to 2026. These analyses will help the reader to understand the potential worth of investment in a particular region. Global Bionic Eye Market: Competitive Landscape This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and production by manufacturers during the forecast period of 2015 to 2019. The major players in the market include Retina Implant AG, Bionic Vision Australia, THE BIONIC EYE, Pixium Vision, iBionics, Second Sight Medical Products, NeoStrata Company, ABIOMED, Berlin Heart, Zimmer Biomet, etc.

Report Objectives

Tracking and analyzing competitive developments in the global Bionic Eye market, including research and development, merger and acquisition, collaboration, and product launch Analyzing core competencies and market shares of leading companies in a comprehensive manner Forecasting the growth of the overall global Bionic Eye market and its important segments on the basis of revenue and volume Pinpointing market opportunities for stakeholders, vendors, market players, and other interested parties Strategically analyzing microeconomic and macroeconomic factors and their influence on future prospects and growth trends of the global Bionic Eye market

Enquire for customization in Report @https://www.qyresearch.com/customize-request/form/1537213/global-bionic-eye-market

TOC

Table of Contents 1 Bionic Eye Market Overview1.1 Product Overview and Scope of Bionic Eye1.2 Bionic Eye Segment by Type1.2.1 Global Bionic Eye Production Growth Rate Comparison by Type 2020 VS 20261.2.2 Electronic1.2.3 Mechanical1.3 Bionic Eye Segment by Application1.3.1 Bionic Eye Consumption Comparison by Application: 2020 VS 20261.3.2 Hospitals1.3.3 Clinics1.3.4 Others1.4 Global Bionic Eye Market by Region1.4.1 Global Bionic Eye Market Size Estimates and Forecasts by Region: 2020 VS 20261.4.2 North America Estimates and Forecasts (2015-2026)1.4.3 Europe Estimates and Forecasts (2015-2026)1.4.4 China Estimates and Forecasts (2015-2026)1.4.5 Japan Estimates and Forecasts (2015-2026)1.4.6 South Korea Estimates and Forecasts (2015-2026)1.5 Global Bionic Eye Growth Prospects1.5.1 Global Bionic Eye Revenue Estimates and Forecasts (2015-2026)1.5.2 Global Bionic Eye Production Capacity Estimates and Forecasts (2015-2026)1.5.3 Global Bionic Eye Production Estimates and Forecasts (2015-2026) 2 Market Competition by Manufacturers2.1 Global Bionic Eye Production Capacity Market Share by Manufacturers (2015-2020)2.2 Global Bionic Eye Revenue Share by Manufacturers (2015-2020)2.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)2.4 Global Bionic Eye Average Price by Manufacturers (2015-2020)2.5 Manufacturers Bionic Eye Production Sites, Area Served, Product Types2.6 Bionic Eye Market Competitive Situation and Trends2.6.1 Bionic Eye Market Concentration Rate2.6.2 Global Top 3 and Top 5 Players Market Share by Revenue2.6.3 Mergers & Acquisitions, Expansion 3 Production Capacity by Region3.1 Global Production Capacity of Bionic Eye Market Share by Regions (2015-2020)3.2 Global Bionic Eye Revenue Market Share by Regions (2015-2020)3.3 Global Bionic Eye Production Capacity, Revenue, Price and Gross Margin (2015-2020)3.4 North America Bionic Eye Production3.4.1 North America Bionic Eye Production Growth Rate (2015-2020)3.4.2 North America Bionic Eye Production Capacity, Revenue, Price and Gross Margin (2015-2020)3.5 Europe Bionic Eye Production3.5.1 Europe Bionic Eye Production Growth Rate (2015-2020)3.5.2 Europe Bionic Eye Production Capacity, Revenue, Price and Gross Margin (2015-2020)3.6 China Bionic Eye Production3.6.1 China Bionic Eye Production Growth Rate (2015-2020)3.6.2 China Bionic Eye Production Capacity, Revenue, Price and Gross Margin (2015-2020)3.7 Japan Bionic Eye Production3.7.1 Japan Bionic Eye Production Growth Rate (2015-2020)3.7.2 Japan Bionic Eye Production Capacity, Revenue, Price and Gross Margin (2015-2020)3.8 South Korea Bionic Eye Production3.8.1 South Korea Bionic Eye Production Growth Rate (2015-2020)3.8.2 South Korea Bionic Eye Production Capacity, Revenue, Price and Gross Margin (2015-2020) 4 Global Bionic Eye Consumption by Regions4.1 Global Bionic Eye Consumption by Regions4.1.1 Global Bionic Eye Consumption by Region4.1.2 Global Bionic Eye Consumption Market Share by Region4.2 North America4.2.1 North America Bionic Eye Consumption by Countries4.2.2 U.S.4.2.3 Canada4.3 Europe4.3.1 Europe Bionic Eye Consumption by Countries4.3.2 Germany4.3.3 France4.3.4 U.K.4.3.5 Italy4.3.6 Russia4.4 Asia Pacific4.4.1 Asia Pacific Bionic Eye Consumption by Region4.4.2 China4.4.3 Japan4.4.4 South Korea4.4.5 Taiwan4.4.6 Southeast Asia4.4.7 India4.4.8 Australia4.5 Latin America4.5.1 Latin America Bionic Eye Consumption by Countries4.5.2 Mexico4.5.3 Brazil 5 Production, Revenue, Price Trend by Type5.1 Global Bionic Eye Production Market Share by Type (2015-2020)5.2 Global Bionic Eye Revenue Market Share by Type (2015-2020)5.3 Global Bionic Eye Price by Type (2015-2020)5.4 Global Bionic Eye Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 6 Global Bionic Eye Market Analysis by Application6.1 Global Bionic Eye Consumption Market Share by Application (2015-2020)6.2 Global Bionic Eye Consumption Growth Rate by Application (2015-2020) 7 Company Profiles and Key Figures in Bionic Eye Business7.1 Retina Implant AG7.1.1 Retina Implant AG Bionic Eye Production Sites and Area Served7.1.2 Retina Implant AG Bionic Eye Product Introduction, Application and Specification7.1.3 Retina Implant AG Bionic Eye Production Capacity, Revenue, Price and Gross Margin (2015-2020)7.1.4 Retina Implant AG Main Business and Markets Served7.2 Bionic Vision Australia7.2.1 Bionic Vision Australia Bionic Eye Production Sites and Area Served7.2.2 Bionic Vision Australia Bionic Eye Product Introduction, Application and Specification7.2.3 Bionic Vision Australia Bionic Eye Production Capacity, Revenue, Price and Gross Margin (2015-2020)7.2.4 Bionic Vision Australia Main Business and Markets Served7.3 THE BIONIC EYE7.3.1 THE BIONIC EYE Bionic Eye Production Sites and Area Served7.3.2 THE BIONIC EYE Bionic Eye Product Introduction, Application and Specification7.3.3 THE BIONIC EYE Bionic Eye Production Capacity, Revenue, Price and Gross Margin (2015-2020)7.3.4 THE BIONIC EYE Main Business and Markets Served7.4 Pixium Vision7.4.1 Pixium Vision Bionic Eye Production Sites and Area Served7.4.2 Pixium Vision Bionic Eye Product Introduction, Application and Specification7.4.3 Pixium Vision Bionic Eye Production Capacity, Revenue, Price and Gross Margin (2015-2020)7.4.4 Pixium Vision Main Business and Markets Served7.5 iBionics7.5.1 iBionics Bionic Eye Production Sites and Area Served7.5.2 iBionics Bionic Eye Product Introduction, Application and Specification7.5.3 iBionics Bionic Eye Production Capacity, Revenue, Price and Gross Margin (2015-2020)7.5.4 iBionics Main Business and Markets Served7.6 Second Sight Medical Products7.6.1 Second Sight Medical Products Bionic Eye Production Sites and Area Served7.6.2 Second Sight Medical Products Bionic Eye Product Introduction, Application and Specification7.6.3 Second Sight Medical Products Bionic Eye Production Capacity, Revenue, Price and Gross Margin (2015-2020)7.6.4 Second Sight Medical Products Main Business and Markets Served7.7 NeoStrata Company7.7.1 NeoStrata Company Bionic Eye Production Sites and Area Served7.7.2 NeoStrata Company Bionic Eye Product Introduction, Application and Specification7.7.3 NeoStrata Company Bionic Eye Production Capacity, Revenue, Price and Gross Margin (2015-2020)7.7.4 NeoStrata Company Main Business and Markets Served7.8 ABIOMED7.8.1 ABIOMED Bionic Eye Production Sites and Area Served7.8.2 ABIOMED Bionic Eye Product Introduction, Application and Specification7.8.3 ABIOMED Bionic Eye Production Capacity, Revenue, Price and Gross Margin (2015-2020)7.8.4 ABIOMED Main Business and Markets Served7.9 Berlin Heart7.9.1 Berlin Heart Bionic Eye Production Sites and Area Served7.9.2 Berlin Heart Bionic Eye Product Introduction, Application and Specification7.9.3 Berlin Heart Bionic Eye Production Capacity, Revenue, Price and Gross Margin (2015-2020)7.9.4 Berlin Heart Main Business and Markets Served7.10 Zimmer Biomet7.10.1 Zimmer Biomet Bionic Eye Production Sites and Area Served7.10.2 Zimmer Biomet Bionic Eye Product Introduction, Application and Specification7.10.3 Zimmer Biomet Bionic Eye Production Capacity, Revenue, Price and Gross Margin (2015-2020)7.10.4 Zimmer Biomet Main Business and Markets Served 8 Bionic Eye Manufacturing Cost Analysis8.1 Bionic Eye Key Raw Materials Analysis8.1.1 Key Raw Materials8.1.2 Key Raw Materials Price Trend8.1.3 Key Suppliers of Raw Materials8.2 Proportion of Manufacturing Cost Structure8.3 Manufacturing Process Analysis of Bionic Eye8.4 Bionic Eye Industrial Chain Analysis 9 Marketing Channel, Distributors and Customers9.1 Marketing Channel9.2 Bionic Eye Distributors List9.3 Bionic Eye Customers 10 Market Dynamics10.1 Market Trends10.2 Opportunities and Drivers10.3 Challenges10.4 Porters Five Forces Analysis 11 Production and Supply Forecast11.1 Global Forecasted Production of Bionic Eye (2021-2026)11.2 Global Forecasted Revenue of Bionic Eye (2021-2026)11.3 Global Forecasted Price of Bionic Eye (2021-2026)11.4 Global Bionic Eye Production Forecast by Regions (2021-2026)11.4.1 North America Bionic Eye Production, Revenue Forecast (2021-2026)11.4.2 Europe Bionic Eye Production, Revenue Forecast (2021-2026)11.4.3 China Bionic Eye Production, Revenue Forecast (2021-2026)11.4.4 Japan Bionic Eye Production, Revenue Forecast (2021-2026)11.4.5 South Korea Bionic Eye Production, Revenue Forecast (2021-2026) 12 Consumption and Demand Forecast12.1 Global Forecasted and Consumption Demand Analysis of Bionic Eye12.2 North America Forecasted Consumption of Bionic Eye by Country12.3 Europe Market Forecasted Consumption of Bionic Eye by Country12.4 Asia Pacific Market Forecasted Consumption of Bionic Eye by Regions12.5 Latin America Forecasted Consumption of Bionic Eye 13 Forecast by Type and by Application (2021-2026)13.1 Global Production, Revenue and Price Forecast by Type (2021-2026)13.1.1 Global Forecasted Production of Bionic Eye by Type (2021-2026)13.1.2 Global Forecasted Revenue of Bionic Eye by Type (2021-2026)13.1.2 Global Forecasted Price of Bionic Eye by Type (2021-2026)13.2 Global Forecasted Consumption of Bionic Eye by Application (2021-2026) 14 Research Finding and Conclusion 15 Methodology and Data Source15.1 Methodology/Research Approach15.1.1 Research Programs/Design15.1.2 Market Size Estimation15.1.3 Market Breakdown and Data Triangulation15.2 Data Source15.2.1 Secondary Sources15.2.2 Primary Sources15.3 Author List15.4 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from the huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become a brand of quality assurance in the consulting industry.

Read more here:
Bionic Eye Market Challenges and Growth Factor By 2026| Bionic Vision Australia, THE BIONIC EYE, Pixium Vision - Weekly Wall

Overview Of Eyesight Test Equipment Industry 2020-2025:

This has brought along several changes in This report also covers the impact of COVID-19 on the global market.

The Eyesight Test Equipment Market analysis summary by Reports Insights is a thorough study of the current trends leading to this vertical trend in various regions. Research summarizes important details related to market share, market size, applications, statistics and sales. In addition, this study emphasizes thorough competition analysis on market prospects, especially growth strategies that market experts claim.

Eyesight Test Equipment Market competition by top manufacturers as follow: , EyeNetra, Bhavana MDC, Essilor International, Alcon, Inc., Heine, Heidelberg Engineering GmbH, Seiko Optical Products Co., Ltd., Nidek Co., Ltd., Carl Zeiss AG, Hoya Corporation, Abbott Medical Optics.Inc., Johnson & Johnson Vision Care.Inc., Shenzhen Certainn Technology

Get a Sample PDF copy of the report @ https://reportsinsights.com/sample/67174

The global Eyesight Test Equipment market has been segmented on the basis of technology, product type, application, distribution channel, end-user, and industry vertical, along with the geography, delivering valuable insights.

The Type Coverage in the Market are: PortableStationary

Market Segment by Applications, covers:ChildrenAdultsThe Elder

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaRest of Asia PacificCentral & South AmericaMiddle East & Africa

Major factors covered in the report:

To get this report at a profitable rate.: https://reportsinsights.com/discount/67174

The analysis objectives of the report are:

Access full Report Description, TOC, Table of Figure, Chart, [emailprotected] https://reportsinsights.com/industry-forecast/Eyesight-Test-Equipment-Market-67174

About US:

Reports Insights is the leading research industry that offers contextual and data-centric research services to its customers across the globe. The firm assists its clients to strategize business policies and accomplish sustainable growth in their respective market domain. The industry provides consulting services, syndicated research reports, and customized research reports.

Contact US:

:(US) +1-214-272-0234

:(APAC) +91-7972263819

Email:[emailprotected]

Sales:[emailprotected]

View original post here:
New Comprehensive Report on Eyesight Test Equipment Market to Witness an Outstanding Growth during 2020 2025 with Top Players Like EyeNetra, Bhavana...

In light of the COVID-19 pandemic, and to protect the type 1 diabetes (T1D) community, the Diabetes Research Connection (DRC) is going virtual with its 3rd annual Dance for Diabetes Under the Sea. John and Tammy in the Morningwill be hosting this event on September 30th at 6pmPT!

The event is FREE and will feature RaeLynn, Uncle Kracker, Tim McGraw, and more!

The Dance for Diabetes will raise necessary funds to support DRCs mission to connect donors with early-career scientists enabling them to perform peer-reviewed, novel research designed to prevent and cure T1D, minimize its complications and improve the quality of life for those living with the disease. Currently, 1.6 million Americans live with this autoimmune disease, including 200,000 children. Approximately 40,000 new patients are diagnosed yearly. Despite these numbers, funding for diabetes research has declined. Of the funding available, 97% goes to established scientists.

Go to diabetesresearchconnection.org/dancefordiabetes to RSVP!

See the rest here:
Join John and Tammy for the 3rd Annual Dance for Diabetes - RADIO.COM

LOS ANGELES For Adam Winney, a 26-year old with Type 1 diabetes, grocery shopping during the early days of a pandemic was an infuriating task. Everything was sold out, except for the one type of food he couldnt eat.

The only things left were carbs, carbs, carbs, the Van Nuys resident said. Ive never been more furious than back in March.

Winneys disease has deprived his body of insulin, a hormone thats needed to turn the sugar in carbohydrates into energy. Without it, his blood sugar can spike to dangerous levels, eventually leading to serious health problems like cardiovascular disease, nerve damage and kidney failure.

But the insulin pens he relies on to keep his body in balance cost him upwards of $1,000 a month, since his health insurance doesnt cover the medication.

After the coronavirus outbreak cost him his job as a receptionist at a hair salon, that expense was beyond his reach. He went six weeks without the long-acting insulin he usually takes every day.

COVID-19 presents a unique set of challenges to the roughly 34 million Americans like Winney who are living with diabetes.

The Centers for Disease Control and Prevention says people with Type 1 diabetes are probably more susceptible to a severe case of COVID-19. Those with Type 2 diabetes the more common form that begins when people lose their sensitivity to insulin are definitely at increased risk of severe COVID-19, according to the CDC.

For instance, a study of more than 7,300 COVID-19 patients in China found that those with Type 2 diabetes needed more medical care and were nearly 50% more likely to die than patients without diabetes.

The risk of death was especially high for people who had trouble controlling their blood sugar, researchers reported. Another study of more than 1,200 COVID-19 patients in the U.S. found that the mortality rate for those with diabetes or high blood sugar was 29%, compared with 6% for those without diabetes.

The extent to which you control your diabetes is a risk factor, said Dr. Daniel Drucker, a senior scientist at the Lunenfeld-Tanenbaum Research Institute at the University of Toronto. Theres a lot we can do about that, by making sure that your diabetes is optimally controlled.

Insulin is essential for keeping blood sugar in check, but the pricey medicine is harder to get if a job disappears, along with the health insurance that came with it.

The cost of insulin varies from patient to patient. It depends on the type of insulin they need some take effect within 15 minutes; others last more than a day _ as well as the dose. Some insurance plans pick up more of the tab than others.

The financial strain brought on by the pandemic has forced Royce Jonathan Miller of Yuba City to consider rationing the insulin he takes for Type 1 diabetes. He has kept his job as an optician at Walmart, but since his father-in-law lost his job at a maintenance company that closed operations due to the pandemic, Miller has become the sole provider for the four people in his household.

Miller has an insulin pump, which uses a tube to continuously deliver a small amount of insulin directly to the pancreas. He is supposed to change out the pieces that connect to his body every three days. Lately, hes been wondering if thats absolutely necessary.

Im starting to think, I can stretch that up for two cycles, every six days, and hopefully it doesnt get infected, Miller said. But I do realize that if I am to make myself sick and wind up in the hospital, that will be a bigger burden.

A nationwide survey of 5,000 people with diabetes conducted for the American Diabetes Assn. found that one in four have rationed supplies to cut the cost of their diabetes care since the start of the pandemic.

Now is not the time to let up on helping these individuals manage their disease, because it may in fact be helpful in preventing them from getting severe COVID-19, Drucker said.

People with Type 2 diabetes may face even greater hardship in affording their insulin, said Dr. Francisco Prieto, a family health physician in Sacramento.

Not everyone who has Type 2 has to take insulin, Prieto said. Those who do are typically folks who either have the most severe cases of diabetes or have failed all the previous oral and injectable treatments. That means they may need to take even more insulin on a daily basis than Type 1 patients, he said.

Since 2019, 11 states have set limits on the amount insurance companies can set as co-payments for insulin. Each of those states has enacted price caps ranging from $25 to $100 per month since the coronavirus outbreak took off in March.

California may soon join the list. In February, Assemblyman Adrin Nazarian, D-North Hollywood, introduced a bill that would cap insulin copays at $50 for a 30-day supply, or $100 per month. It passed in June by a 64-4-11 vote, but the Senate Health Committee has not scheduled a hearing that would allow the bill to move forward.

Winney said a price cap would give him some peace of mind. These days he relies on free samples provided by one of his doctors, but that generosity may not last.

I see that as an incentive to finally change insurance, he said.

Ensuring an affordable supply of insulin would help people with diabetes manage their disease better, said Brandi DaVeiga, a stay-at-home mom in Lakewood with Type 1 diabetes. She has good coverage now through her husbands health insurance plan, but when she was between plans three years ago, she began skipping insulin doses to make her supply last longer. On several occasions, her blood sugar levels rose dangerously high, and she ended up in the emergency room.

Its really stressful, she said of managing diabetes during a pandemic. And that doesnt help your blood sugar.

The fact that people with diabetes are rationing their insulin when they need it most points to larger problems with health care access in this country, Drucker said.

COVID-19 is reminding us of the importance of doing everything we can in our vulnerable, at-risk populations, he said. Lets do everything we can to optimize their health because that may, in turn, reduce their risk of having a bad outcome with this virus.

See the original post here:
Amid COVID-19 pandemic, people with diabetes struggle to get insulin - Press of Atlantic City

Non-invasive Blood Glucose Monitoring Devices Market: Introduction

Diabetes is a chronic disease that affects more than 8.5% of the global population. Monitoring the blood glucose levels (BGLs) on a regular basis is necessary to manage diabetes progression. Non-invasive blood glucose monitoring devices use painless procedure for continuous tracking of a patients glucose level. Increase in demand for smart diabetes management devices due to the technologically advanced features is anticipated to drive the market.

Read Report Overview - https://www.transparencymarketresearch.com/noninvasive-blood-glucose-monitoring-devices-market.html

Key Drivers and Restraints of Global Non-invasive Blood Glucose Monitoring Devices Market

Diabetes has evolved as one of the principal health care epidemics of the modern era. Prevalence of diabetes is rising due to change in lifestyle, environmental factors, and genetic mutation. Moreover, obesity is a key risk factor for diabetes. According to the American Diabetes Association, an estimated 30.3 million people in the U.S. had diabetes in 2015; among these 1.25 million were children. According to the British Diabetic Association operating as Diabetes UK, 3.8 million people were diagnosed with diabetes in the U.K. in 2019. According to Diabetes U.K., 382 million adults across the globe aged between 20 and 79 had diabetes in 2012. This number is expected to reach 592 million by 2035. An estimated 175 million people are undiagnosed with type 2 diabetes. Prevalence of diabetes is variable and is expected to increase in the near future.

Continuous advancement in technologies also boosts market growth. Researchers are focusing on electromagnetism (EM) as a leading technology to achieve non-invasive and continuous glucose monitoring. Launch of new products also fuels the growth of the global market. In January 2020, Integrity Applications, Inc. received CE Mark approval for a major enhancement to GlucoTrack, allowing users to perform the calibration process by themselves, without the need of a certified calibrator.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=78494

Non-invasive glucose monitoring devices are based on various technologies, which detect characterization of the biological properties of the skin or biological fluids. The accuracy offered by these types of product is not close to that of minimally invasive CGM devices under uncontrolled conditions. This factor is likely to hamper the growth of the global market.

Spectroscopy to Dominate Global Non-invasive Blood Glucose Monitoring Devices Market

In terms of technology, the global non-invasive blood glucose monitoring devices market can be divided into spectroscopy, microwave/RF sensing, electromagnetic, thermal, ultrasonic and others

Spectroscopy technology-based devices dominated the global market in terms of revenue in 2019. The technology is based on the direct effect of glucose on the scattering properties of the organ. Diabetes and its complications impose significant economic consequences on individuals, families, health systems, and countries. This non-invasive process is fast, painless, and cost-effective. OrSense's NBM device is based on occlusion spectroscopy, which is a proprietary technology aimed toward assuring accurate, convenient, and affordable glucose monitoring.

Request for Analysis of COVID-19 Impact on Non-invasive Blood Glucose Monitoring Devices Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=78494

Wearable to Lead Global Non-invasive Blood Glucose Monitoring Devices Market

Based on modality, the global non-invasive blood glucose monitoring devices market can be bifurcated into wearable and non-wearable/table-top

The wearable segment dominated the global market in terms of revenue in 2019. Requirement of painless, needle-free, and continuous glucose monitoring sensors to enhance the quality of life of diabetic patients is a major factor driving the segment. AerBetic manufactures a non-invasive wearable diabetes monitor that continuously provides blood sugar levels. It also comes with an application that allows a user to set up alerts in order to communicate to a network of health care providers.

Home Care Segment to Witness Significant Growth

In terms of end user, the global non-invasive blood glucose monitoring devices market can be categorized into hospitals, home care, and clinics

The home care segment held the largest share of the global market in 2019. Advancements in mobile health & connected devices, remote patient monitoring, and telehealth augment the self/home health care management of diabetes. Additionally, preference for treatment of diabetes at home is likely to propel the segment. Inclination toward self-management devices is a key factor projected to drive the segment.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=78494

North America to Dominate Global Non-invasive Blood Glucose Monitoring Devices Market

In terms of region, the global non-invasive blood glucose monitoring devices market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

In terms of revenue, North America dominated the global non-invasive blood glucose monitoring devices market in 2019, followed by Europe. High prevalence of diseases and well-established health care infrastructure that enables proper diagnosis are attributed to the regions large market share. According to the American Diabetes Association, in 2018, 34.2 million people in the U.S., or 10.5% of the population, had diabetes. Moreover, 1.6 million people have type 1 diabetes, including about 187,000 children and adolescents.

However, the market in Asia Pacific is expected to grow at a rapid pace during the forecast period primarily due to rise in prevalence of diabetes and increase in awareness about diagnosis & treatment. Majority of countries in Asia Pacific are economically developing and a number of players are making significant investments in the region. These factors boost the growth of the market in Asia Pacific. According to the International Diabetes Federation (IDF), prevalence of diabetes has increased in developing countries due to rapid and ongoing socioeconomic transition and it is likely to rise further.

Pre Book Non-invasive Blood Glucose Monitoring Devices Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=78494&ltype=S

Key Players Operating in Market

The global non-invasive blood glucose monitoring devices market was highly fragmented in 2019. Key players operating in the global market are:

Browse More Trending Reports by Transparency Market Research:

Vaginitis Therapeutics Market: https://www.transparencymarketresearch.com/vaginitis-therapeutics-market.html

Anti allergic Therapeutics Market: https://www.transparencymarketresearch.com/antiallergic-therapeutics-market.html

Aseptic Meningitis Treatment Market: https://www.transparencymarketresearch.com/aseptic-meningitis-treatment-market.html

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactMr. Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: https://www.transparencymarketresearch.com/

Go here to read the rest:
Non-invasive Blood Glucose Monitoring Devices Market: Wearable segment dominated the global market in terms of revenue - BioSpace